Archive for the ‘Cell Therapy’ Category

Dr Lox Stem Cell Therapy WFLA News 8
Dr. Lox | http://www.drlox.com | 727-462-5582 (WFLA) When Judy Loar, 68, could not bear to walk any longer due to excruciating pain in both of her knees from degenerative joint disease, she did what...

By: Dr. Lox

Excerpt from:
Dr Lox Stem Cell Therapy WFLA News 8 - Video

stem cell therapy Egypt
/ 01002527255 : http://www.facebook.com/espcr.

By:

Read the rest here:
stem cell therapy Egypt - Video

treatment available for autism spectrum disorder
After stem cell therapy treatment available for autism spectrum disorder parents of the child from London United Kingdom testifying most of the amazing improvements they saw after stem cell...

By: Neurogen Brain and Spine Institute

See the original post here:
treatment available for autism spectrum disorder - Video

PUBLIC RELEASE DATE:

16-Jun-2014

Contact: Colin Poitras colin.poitras@uconn.edu 860-486-4656 University of Connecticut

Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models and offered better treatment results than stem cells derived from human adult bone marrow.

The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

"The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticut's Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside," says Professor Marc Lalande, director of the UConn's Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticut's Stem Cell Research Program that was awarded to ImStem and Professor Pachter's lab.

"Connecticut's investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research," says Gov. Dannel P. Malloy. "This new study moves us one step closer to a stem cell-based clinical product that could improve people's lives."

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

Originally posted here:
Embryonic stem cells offer new treatment for multiple sclerosis

Dr. Omar Gonzalez presents his Integrative Medicine Clinic in Mexico
http://www.placidway.com/profile/705/ - Watch this Video as Dr.Omar Gonzalez, MD, specialist in Stem Cell Therapy, Integrative Medicine and Chronic Diseases, presents his new clinic located...

By: placidways

Follow this link:
Dr. Omar Gonzalez presents his Integrative Medicine Clinic in Mexico - Video

DUBLIN, June 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/v969qd/cell_separation) has announced the addition of the "Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

This report consists of the market analysis for the various technologies used in the cell separation market. Increasing cell therapy oriented research and development globally is driving the cell separation technologies market towards significant growth. The stakeholders for this report include providers and manufacturers of cell separation technology instruments.

The cell separation technologies market is segmented on the basis of technologies that are available in the market and application areas of cell separation technologies. The various technology segments covered in this report are gradient centrifugation and separation based on surface markers. Separation based on surface markers technology include two different techniques namely, magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS).

The application areas of cell separation technologies comprise stem cell research, immunology, neuroscience research and cancer research. Revenue forecast and market analysis for each segment has been given in this study for the period of 2011 to 2019 in terms of USD million in addition to the compound annual growth rate (CAGR %) for each segment of technology and application. The CAGR is provided for forecast period of 2013 to 2019 and 2012 have been considered as base in year for market size estimation.

Geographically, global cell separation technologies market has been segmented into four areas namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). This report also provides the present and future market estimation in terms of USD million for the period 2011 to 2019, in addition to compound annual growth rate (CAGR %) for each geographic area. Further to market size estimation, this report provides recommendations and highlights of the market that should be useful for current and new market players to grow and sustain in the global cell separation technologies market.

Market trends and dynamics such as restraints, opportunities and growth drivers that have impact on present and future position of this market are demonstrated in the market overview chapter of this study. In addition, the market overview chapter also consists of Porter's five forces analysis and market attractiveness by geography to give detailed analysis of the entire competitive status of the global cell separation technologies market.

Key information about the top market players operating in the global cell separation technologies market is given in the company profiles section of this report. Some of the key players profiled in this report include BD Bioscience, EMD Millipore, Mitenyi Biotec GmbH, and STEMCELL Technologies, Terumo BCT, pluriSelect GmbH, and Life Technologies (Thermo Fisher Scientific, Inc.).

Key Topics Covered:

Chapter 1 Introduction

Visit link:
Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

PUBLIC RELEASE DATE:

9-Jun-2014

Contact: Kimberly Brown kbrown@snmmi.org 703-652-6773 Society of Nuclear Medicine

St. Louis, Mo. (June 9, 2014) Researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting revealed how a protein encourages the production of stem cells that regenerate damaged tissues of the heart following an acute attack (myocardial infarction). They further assert that it has a better chance of working if provided early in treatment. This was confirmed by molecular imaging, which captured patients' improved heart health after therapy.

If given after a heart attack, granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow stem cells that turn down the collateral damage of cell death that occurs after acute myocardial infarction. Other research has shown G-CSF having a beneficial impact on left ventricle ejection fraction, a measurement of how powerfully the heart is pumping oxygenated blood back into the aorta and the rest of the body with each beat. The objective of this study was to find out how beneficial the stem cellstimulating therapy would be if administered early during standard treatment. Early prescription of G-CSF happens to strengthen its effect immediately and after follow up.

"Previous studies have shown that giving G-CSF to unselected heart attack patients failed to satisfactorily improve their condition, but G-CSF may potentially be beneficial if given earlier than 37 hours following myocardial infarction and coronary intervention," remarked Takuji Toyama, MD, the study's principal researcher from the division of cardiology at Gunma Prefectural Cardiovascular Center in Maebashi, Japan. "This study shows that the first intravenous drip infusion of G-CSF during treatment just after hospitalization was able to rescue our patients. I am confident that with additional data from a forthcoming clinical trial, this protocol can be adopted as a standard of practice."

For this study, 40 consecutive patients with acute myocardial infarction were given either G-CSF therapy or saline intravenously for a total of five days beginning during a selected minimally invasive treatment, otherwise known as percutaneous cardiac intervention. Results of one year's worth of SPECT stress tests nailed how earlier start of G-CSF therapy in heart attack patients improves blood flow, access to essential energy and overall cardiac function.

Coronary heart disease caused one out of every six fatalities in the U.S. in 2010, according to 2014 statistics from the American Heart Association. An estimated 620,000 Americans suffered a first heart attack, and 295,000 had a recurrent episode. Collectively, heart attacks occur about once every 34 seconds. Coronary events cause about 379,559 deaths each year.

###

Scientific Paper 239: Takuji Toyama, Hiroshi Hoshizaki, Hakuken Kan, Ren Kawaguchi, Hitoshi Adachi, Shigeru Ohsima, Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan; Masahiko Kurabayashi, Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan, "Is the granulocyte colony-stimulating factor therapy in the earliest phase effective to rescue patients with acute myocardial infarction?" SNMMI's 61th Annual Meeting, June 7, 2014, St. Louis, Missouri.

Originally posted here:
Stem cell-stimulating therapy saves heart attack patients

Knee and shoulder arthritis/torn rotator cuffs 16 months after stem cell therapy by Dr Harry Adelson
Mike discusses his results 16 months after stem cell therapy for his arthritic knees and shoulders and torn rotator cuffs by Dr Harry Adelson at http://www.docerecl...

By: Harry Adelson, N.D.

See the original post:
Knee and shoulder arthritis/torn rotator cuffs 16 months after stem cell therapy by Dr Harry Adelson - Video

La Jolla, CA (PRWEB) June 17, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced their newest clinical study for Multiple Sclerosis. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

This clinical study is bringing to the field a new, unique type of stem cell therapy that has the possibility of being more effective than other stem cell treatments currently available. Patients who receive stem cell treatment through StemGenex for Multiple Sclerosis will receive StemGenex multiple administration protocol. This consists of four targeted administration methods of the stem cells to deliver the necessary amount of stem cells past the blood brain barrier.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, "Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage. We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data."

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell treatment. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.

Rita Alexander, founder and president of StemGenex, stated, This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with Multiple Sclerosis. The average lifetime cost of current standard of care treatment per MS patient is $1.2 million. The human cost of the disease including pain and suffering endured by MS patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDoles research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinsons and Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com

More here:
StemGenex Announces New Stem Cell Clinical Study for Multiple Sclerosis

Contact Information

Available for logged-in reporters only

Newswise LOS ANGELES (June 17, 2014) Stem cell therapy for cardiovascular disease isnt a medical pipe dream its a reality today, although patients need to better understand the complex science behind these experimental treatments, according to the chief of Cardiology for the Cedars-Sinai Heart Institute.

In a 17-minute TEDxGrandForks talk now available on YouTube.com, Timothy D. Henry, MD, known for his innovative work in developing stem cell treatments for advanced heart disease patients, said he understands why so many are confused about the latest scientific findings.

Most people today get our information from sound bites, and the issues surrounding stem cells are too complex to be fully explained in a single catchy phrase, Henry said, adding, We have far too much controversy about stem cells and far too much hype.

Stem cell science has become a political dividing line with many opposing research into stem cells derived from human embryos, Henry said. However, he said, todays leading-edge clinical research focuses on stem cells derived from adults that can be scientifically programmed to become a specialized cell, such as a heart cell or a brain cell, thereby avoiding the ethical questions involved in embryonic research.

Very few of the cells we give actually become muscle or actually become blood vessels, Henry said. What they do is increase growth factors and encourage natural cells in the body to generate new, healthy tissue.

The Cedars-Sinai Heart Institute, directed by Eduardo Marbn, MD, PhD, is a world leader in studying the use of stem cells to regenerate heart muscle in patients who have had heart attacks. In 2009, Cedars-Sinai physicians conducted the first infusion of stem cells into heart attack patients, using stem cells grown from the patients own heart tissue. The resulting study, published in February 2012 in The Lancet, showed that patients who underwent the stem cell procedure experienced a significant reduction in the size of the scar left behind by a heart attack. Patients also experienced a sizable increase in healthy heart muscle following the experimental stem cell treatments.

Currently, Henry is co-directing a new stem cell study with Raj Makkar, MD, director of Interventional Cardiology. The national trial, called ALLSTAR, uses heart cells from unrelated donors in an effort to reverse lasting tissue damage after a heart attack.

During his talk, Henry also expressed concern for patients who might be taken advantage of by unscrupulous clinics outside of the United States that offer stem cell cures for everything from neurological diseases to baldness. Patients also need to understand that stem cell science has a long way to go before regenerative medicine treatments are widely available.

See the original post here:
Stem Cell Expert Explains How Experimental Regenerative Medicine Therapies Can Regrow Damaged Heart Muscle

Obesity Weight (Stem Cell Therapy)
The subject matter of this video Obesity Weight.

By: Mohammad Sadique

See the rest here:
Obesity & Weight (Stem Cell Therapy) - Video

Stem cell therapy | stem cells laboratory chip osteoarthritis
http://www.arthritistreatmentcenter.com A 3 D lab chip for osteoarthritis... learn more next... Living human cartilage grown on lab chip In Business Standard, scientists have created the...

By: Nathan Wei

Go here to see the original:
Stem cell therapy | stem cells laboratory chip osteoarthritis - Video

How do Stem Cell Therapy Work?
by Danny Yang.

By: Marieke van Lankvelt

Continued here:
How do Stem Cell Therapy Work? - Video

Beverly HIlls, California (PRWEB) June 09, 2014

The top stem cell doctor in Beverly Hills and Los Angeles at Beverly Hills Orthopedic Institute are now offering stem cell procedures for hip arthritis. The stem cell therapy typically provides pain relief along with being able to delay or avoid the need for joint replacement. Call (310) 438-5343 for more information and scheduling.

Dr. Raj, Medical Director at Beverly Hills Orthopedic Institute, is a Double Board Certified orthopedic doctor who has been a pioneer in stem cell therapy for musculoskeletal conditions. Several types of stem cell procedures are offered including bone marrow derived along with amniotic derived procedures.

For the bone marrow stem cell procedures, a short outpatient procedure involves harvesting bone marrow from the patient's iliac crest. The stem cells are immediately processed to concentrate the growth factors and cells, and then they are injected into the hip for pain relief and tissue regeneration.

For the amniotic derived procedures, the fluid is obtained from consenting donors after a scheduled c-section procedure. There is no fetal tissue utilized, and the fluid is processed at an FDA regulated laboratory. An immense amount of stem cells, growth factors and hyaluronic acid are present in the amniotic material.

Dr. Raj has performed a significant amount of stem cell procedures utilizing both methods for hip arthritis, with the results being stellar to date. Being Double Board Certified and a sports medicine expert, Dr. Raj also offers stem cell procedures for sports injuries such as tendonitis and ligament injuries. This includes rotator cuff tendonitis, knee injuries, elbow tendonitis and more.

Beverly Hills Orthopedic Institute is the premier stem cell clinic in Los Angeles and Beverly Hills. Dr. Raj is an ABC News Medical Correspondent and a WebMD Medical Expert. For information on how stem cell therapy can help, call Beverly Hills Orthopedic Institute at (310) 438-5343.

Read the original here:
Beverly Hills Orthopedic Institute Now Offering Revolutionary Stem Cell Procedures for Hip Arthritis to Avoid Joint ...

Stem Cell Therapy Market by Treatment Mode Therapeutic Applications - 2020
[196 Slides Report] Stem Cell Therapy Market report categories the Global market by Therapeutic Applications (CNS, CVS, Musculoskeletal, Wound Healing, GIT, Eye, Immune System), Treatment...

By: James Evans

See original here:
Stem Cell Therapy Market by Treatment Mode & Therapeutic Applications - 2020 - Video

Arthritic hip, knee, and thumbs 9 months after stem cell therapy by Dr Harry Adelson
Raymond and Nina describe their outcomes from stem cell therapy by Dr Harry Adelson for their various arthritic pains http://www.docereclinics.com.

By: Harry Adelson, N.D.

See the rest here:
Arthritic hip, knee, and thumbs 9 months after stem cell therapy by Dr Harry Adelson - Video

New York, NY (PRWEB) June 04, 2014

The Animal Medical Center of New York is offering stem cell therapy provided through Vet-Stem and long-term management in a clinical trial for qualifying cats with chronic kidney disease (CKD). The ultimate goal of this study is to investigate the use of stem cells (obtained from the patients own fat) in aiding the enhancement of renal (kidney) function by their regenerative capabilities, with the goal of improving survival in cats with CKD.

Currently there are no therapeutic options for cats with CKD other than renal transplantation, which is not typically an option for most owners. Most efforts aim at improving uremic signs with food, dietary supplements, and antacids, but there are no current methods for improving function of the kidney directly. CKD is the leading cause of death in older cats, and 35% of cats will develop CKD at some point.

Since renal failure is so common in cats and renal cell death is the ultimate result, improving the health and environment of the cells that remain could improve the overall function of the kidneys and ultimately improve the survival times and quality of life in patients. The aim is to use the cats own adipose (fat) derived stem cells to improve renal function directly, as stem cells are thought to improve, repair, and aid in the growth of damaged tissue.

The potential health benefits of using stem cells to combat CKD include renal regeneration, anti-fibrotic effects, a decrease in proteinuria (also called urine albumin or an abnormal amount of protein in the urine), and an improvement in the Glomerular Filtration Rate (GFR used to help measure kidney function). AMC is offering free fat collection, isolation of the stem cells from the fat, and intra-arterial injection for qualifying cats, as well as free follow-up for three years. Qualifying cats must be diagnosed with IRIS Stage 3 CKD that have had no other experimental therapies. Potential candidates must undergo a full workup and have no history of urinary tract stone disease or the presence of other concurrent, unrelated disease.

Allyson Berent, DVM, DACVIM and Catherine E. Langston, DVM, DACVIM will be leading the three year study, and invite owners with a cat that has been diagnosed with CKD to call 212.329.8763 for more information on qualifying for the clinic trial. To learn more about the study go to http://www.amcny.org/clinicaltrials. To watch a short special interest film about one cats success go to http://www.vet-stem.com/pr_detail.php?id=49.

The Animal Medical Center in New York City is a federally recognized 501(c)(3) non-profit veterinary center that has been a national leader in animal care since 1910. As an academic veterinary hospital, The AMC promotes the health and well-being of companion animals through advanced treatment, research and education. Stem Cell Therapy through Vet-Stem has been offered at AMC since 2008 to treat pain associated with chronic osteoarthritis. To find out more about AMC and their stem cell therapy services for osteoarthritis go to http://www.amcny.org/surgery/neurosurgery/stem-cell-therapy.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read this article:
Animal Medical Center of New York Seeks Candidates for Clinical Trial for Cats with Chronic Kidney Disease to Receive ...

stem cell therapy - treatment for mr with delayed milestones by dr alok sharma, mumbai, india
after stem cell therapy treatment for mental retardation with delayed milestones by dr alok sharma, mumbai, india. Stem Cell Therapy done date 18/02/2013 After Stem Cell Therapy OT assessment:...

By: Neurogen Brain and Spine Institute

The rest is here:
stem cell therapy - treatment for mr with delayed milestones by dr alok sharma, mumbai, india - Video

(2009-04a) David Steenblock MS DO - Bone marrow stem cell therapy
David Steenblock MS DO - Bone marrow stem cell therapy 2009-04-16 part 1 April 16, 2009 Visit the Silicon Valley Health Institute (aka Smart Life Forum) at http://www.svhi.com Silicon Valley...

By: Silicon Valley Health Institute

Read more here:
(2009-04a) David Steenblock MS DO - Bone marrow stem cell therapy - Video

(2006-06) David Steenblock - Umbilical Cord Stem Cell Therapy
David Steenblock Umbilical cord stem cell therapy 2006-06-15 Visit the Silicon Valley Health Institute (aka Smart Life Forum) at http://www.svhi.com Silicon Valley Health Institute Smart...

By: Silicon Valley Health Institute

Read more here:
(2006-06) David Steenblock - Umbilical Cord Stem Cell Therapy - Video

Patients do not have an automatic right to a compassionate therapy for which there is no scientific evidence of efficacy, according to a landmark ruling of the European Court of Human Rights in Strasbourg.

The 28 May ruling referred to the case of Nivio Durisotto, whose daughter suffers a degenerative brain disease. He wished her to be treated with a controversial stem cell-based therapy offered by the Stamina Foundation, based in Brescia, Italy.

But more generally, it will guide any judge facing requests from desperate patients for access to unproved therapies promoted from outside the regulated medical sector.

The judgement is yet another blow for the Stamina Foundation, whose president, Davide Vannoni, is now facing charges of fraudulently obtaining public money to support his therapy.

The Italian Medicines Agency had closed down the Stamina operations in August 2012 on safety grounds (see Leaked files slam stem-cell therapy). In March 2013, the government issued a decree allowing patients to continue Stamina treatment if they had already begun.

Then on 11 September, 2013 an expert committee appointed by the health ministry to examine the Stamina method concluded that there was no evidence to indicate that it might be efficacious (see Advisers declare Italian stem-cell therapy unscientific). The committee further warned that it could be dangerous.

With encouragement from Vannoni, some patients appealed to courts for the right to treatment with the Stamina method. Some judges ruled that the treatment should be given on compassionate grounds, while others including the judge in the Durisotto case ruled that compassionate therapy was not justified because there was no scientific evidence of efficacy.

Durisotto brought his appeal to the European Court of Human Rights on 28 September, 2013 a month after losing his case in Italy.

The European Court dismissed Durisottos claim, saying that the Italian courts ruling had pursued the legitimate aim of protecting health and was proportionate to that aim. It further said that the Italian courts decision had been properly reasoned and was not arbitrary, and that the therapeutic value of the Stamina method had, to date, not yet been proven scientifically. Because the case had been appropriately reasoned, it said, Durisottos daughter had not been discriminated against even if some other national courts had allowed the therapy for similar medical conditions.

Munich-based patent lawyer Clara Sattler de Sousa e Brito, an expert in biomedical laws, says that this clear ruling that scientific proof is necessary will help avoid the use of unproven therapies for so-called compassionate purposes in the future.

Read the rest here:
Human rights court rules that evidence must support compassionate therapy

Block GmbH Centre for Living Cell Therapy
The fresh cell therapy/stem cell therapy is always a full body treatment. The improvement of the function of individual organs also affects all other organs positively.

By: VIPiChannel

Read the original post:
Block GmbH Centre for Living Cell Therapy - Video

SINGAPORE: Australia-based stem cell therapy firm Mesoblast has announced plans to accelerate commercial manufacturing operations in Singapore.

This is to prepare for new product launches in the United States and other major markets over the next couple of years.

Its existing operations in Singapore include making stem cell products for clinical trials under its contract with its partner, pharmaceutical company Lonza.

One of its key products still awaiting full approval is Prochymal, which Mesoblast says can help to more than double the survival rate of patients suffering from complications after receiving tissue transplants from donors -- known as graft versus host disease.

The global stem cell market is expected to grow at an average annual rate of 12 per cent between 2011 and 2016 to reach more than S$8 billion by 2016.

Mesoblast said commercial manufacturing requires a much larger capacity and operations must be scaled-up to meet regulatory demands.

Silviu Itescu, chief executive at Mesoblast, said: "We are now in a phase of making more investments in order to get our processes to commercial scale. That anticipates successful commercial launches.

"If we're successful in that over the next 18-24 months, then we're going to leverage the investment in our commercial facilities to be able to build up and prepare for launching of much larger opportunities in cardiovascular medicine, orthopaedics and diseases of immunity and inflammation which would require purpose-built facilities."

See original here:
Mesoblast to accelerate operations in S'pore

AUTOLOGOUS Adipose Stem Cells

Stem Cell Therapy is not a new technology. As a matter of fact it has been around for more that 60 years now. The problem is most people know it as a bone marrow transplant. And well when you finish saying that people are already screaming "That's Painful". A bone marrow transplant essentially extracts stem cells from your own bone marrow and then returns them back to you. It has been used to help people suffering from conditions like Leukemia and Lymph Node Cancer.

How does it work? Stem Cells hone in on "chemokine" signals that are secreted by injury. When they arrive they alert regenerative cells to go to work and repair the damage, or grow tissue.

At birth, the human body has around 80 million active stem cells working. At age 40 we have less than 25 million active stem cells working. Therefore it takes longer for the body to heal and in some cases damage is often ignored. This is the aging or degeneration process of the body.

In 1998 a little known about Bio Tech Company discovered that there was an enormous amount of stem cells in abdominal fat, commonly referred to as Adipose fat. In fact there are about 1-2 million stem cells and regenerative cells in 1 cc of abdominal fat. Bone marrow contains less than 10% of that. The stem cells in the abdomen are in a dormant or inactive state. The challenge lay only in how to activate them.

In early 2000 the problem had been solved. A special separation process was used to isolate stem cells from abdominal fat and a perfected heliotherapy process activated the stem cells. These super-charged stem cells were now ready to go to work healing your body.

Fat Stem Cell Therapy has been used for over a decade now as therapy for a variety of medical problems as well as an alternative to painful cosmetic surgery. Fat Stem Cell Therapy can help patients suffering from medical conditions such as, Osteoarthritis, Pulmonary Disease, and Diabetes Type II, as well as some Cosmetic Procedures like Face Lifts, Breast Augmentation, and Anti-Aging.

Infinite Horizons Medical Center and its association with a leading Bio Tech company are able to deliver these high tech therapies with precision, expertise and a level of care which rivals any in the world. These painless medical procedures uses the clients' own adult stem cells to treat clients' medical problems. The procedures themselves take roughly 3.5 - 7 hours to complete.

The procedure involves extracting autologous adipose stem cells, enriching them, activating the enriched stem cells and finally returning these stem cells back into the clients' body. The procedure only requires a local anesthetic, is 100% safe, 100% effective and there is a 0% chance of rejection. For more detailed information see our procedure page.

Infinite Horizons Medical Center has put together an incredible program for clients in search of medical treatment with fat stem cell therapy for, Pulmonary Disorders, like IPF or COPD, Diabetes Type II and Osteoarthritis. It has also put together special programs with fat stem cell therapy for cosmetic procedures like Anti-Aging, Breast Augmentation and Face Lifts.

Link:
Fat Stem Cell Therapy | Medical Treatments Cosmetic Procedures

Stem Cell Research & Therapy is the major forum for translational research into stem cell therapies. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into stem cell therapeutics and regenerative therapies, including animal models and clinical trials. The journal also provides reviews, viewpoints, commentaries and reports.

There has been an error retrieving the data. Please try again.

Immortalization of adipose-derived stromal cells

Immortalized human adipose-derived stromal cells maintain most of their original mesenchymal features, in particular the capability to produce significant amounts of angiogenic factors, with potential advantages for laboratory research and regenerative medicine.

Markers of cellular aging in cultured MSCs

Specific gene markers which distinguish aging multipotent stromal cells (MSCs) grown in culture are identified through gene expression profiling using microarray technology.

WJ-MSC transplantation in diabetes

Treatment with Whartons jelly mesenchymal stem cells (WJ-MSC) can improve metabolic control and beta cell function in patients with type 2 diabetes mellitus.

Cell-based therapy in ophthalmology

Debashish Das and colleagues review the stem cell populations of the eye and their respective functions in cell-based therapy and regenerative medicine in ophthalmology.

Continued here:
Stem Cell Research & Therapy